These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 29055286)

  • 1. In Defense of Progesterone: A Review of the Literature.
    Lieberman A; Curtis L
    Altern Ther Health Med; 2017 Nov; 23(6):24-32. PubMed ID: 29055286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progesterone vs. synthetic progestins and the risk of breast cancer: a systematic review and meta-analysis.
    Asi N; Mohammed K; Haydour Q; Gionfriddo MR; Vargas OL; Prokop LJ; Faubion SS; Murad MH
    Syst Rev; 2016 Jul; 5(1):121. PubMed ID: 27456847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progestins and progesterone in hormone replacement therapy and the risk of breast cancer.
    Campagnoli C; Clavel-Chapelon F; Kaaks R; Peris C; Berrino F
    J Steroid Biochem Mol Biol; 2005 Jul; 96(2):95-108. PubMed ID: 15908197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pregnancy, progesterone and progestins in relation to breast cancer risk.
    Campagnoli C; Abbà C; Ambroggio S; Peris C
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):441-50. PubMed ID: 16249080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Could transdermal estradiol + progesterone be a safer postmenopausal HRT? A review.
    L'hermite M; Simoncini T; Fuller S; Genazzani AR
    Maturitas; 2008; 60(3-4):185-201. PubMed ID: 18775609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The bioidentical hormone debate: are bioidentical hormones (estradiol, estriol, and progesterone) safer or more efficacious than commonly used synthetic versions in hormone replacement therapy?
    Holtorf K
    Postgrad Med; 2009 Jan; 121(1):73-85. PubMed ID: 19179815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progesterone or progestin as menopausal ovarian hormone therapy: recent physiology-based clinical evidence.
    Prior JC
    Curr Opin Endocrinol Diabetes Obes; 2015 Dec; 22(6):495-501. PubMed ID: 26512775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progesterone, progestins and the breast in menopause treatment.
    Gompel A; Plu-Bureau G
    Climacteric; 2018 Aug; 21(4):326-332. PubMed ID: 29852797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys.
    Wood CE; Register TC; Lees CJ; Chen H; Kimrey S; Cline JM
    Breast Cancer Res Treat; 2007 Jan; 101(2):125-34. PubMed ID: 16841178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the cardiovascular and breast actions of drospirenone in preclinical studies.
    Simoncini T; Genazzani AR
    Climacteric; 2010 Feb; 13(1):22-33. PubMed ID: 19938948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progestins in preventive hormone therapy. Including pharmacology of the new progestins, desogestrel, norgestimate, and gestodene: are there advantages?
    Sobel NB
    Obstet Gynecol Clin North Am; 1994 Jun; 21(2):299-319. PubMed ID: 7936546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Micronized progesterone, progestins, and menopause hormone therapy.
    Hipolito Rodrigues MA; Gompel A
    Women Health; 2021 Jan; 61(1):3-14. PubMed ID: 32957843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestins and breast cancer: an epidemiologic review.
    Staffa JA; Newschaffer CJ; Jones JK; Miller V
    Fertil Steril; 1992 Mar; 57(3):473-91. PubMed ID: 1740192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel perspectives for progesterone in hormone replacement therapy, with special reference to the nervous system.
    Schumacher M; Guennoun R; Ghoumari A; Massaad C; Robert F; El-Etr M; Akwa Y; Rajkowski K; Baulieu EE
    Endocr Rev; 2007 Jun; 28(4):387-439. PubMed ID: 17431228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
    Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
    Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidemiologic aspects of exogenous progestagens in relation to their role in pathogenesis of human breast cancer.
    van Leeuwen FE
    Acta Endocrinol (Copenh); 1991; 125 Suppl 1():13-26. PubMed ID: 1801500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
    Birrell SN; Butler LM; Harris JM; Buchanan G; Tilley WD
    FASEB J; 2007 Aug; 21(10):2285-93. PubMed ID: 17413000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progesterone and related progestins: potential new health benefits.
    Sitruk-Ware R; El-Etr M
    Climacteric; 2013 Aug; 16 Suppl 1():69-78. PubMed ID: 23647429
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.